secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001641172-25-023489
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q2 net loss narrows to $4.33M; LP-184 Phase 1a complete, complete responses in two trials
--------------------------------------------------------------------------------

- Q2 2025 net loss $4.33M ($0.40/share) vs $4.96M ($0.46) a year ago; cash $15.9M as of June 30, 2025.
- LP-184 Phase 1a enrollment complete (65 patients); MTD and RP2D established; advancing to Phase 1b/2 in TNBC and bladder cancer.
- LP-300 HARMONIC trial shows complete response in a 70-year-old NSCLC patient who failed three prior therapies.
- LP-284 achieves complete metabolic response in heavily pretreated DLBCL patient after two cycles.
- Cash runway extends at least into June 2026; no quarterly earnings call planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000164117225023489/0001641172-25-023489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000164117225023489/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer